


WNT-pathway medulloblastoma: What constitutes low-risk and how low can one go?

February 27 2023



Comparison of progression-free survival (A) and overall survival (B) between children. Credit: *Oncotarget* (2023). DOI: 10.18632/oncotarget.28360

A new research perspective was published in *Oncotarget*. The paper is titled "WNT-pathway medulloblastoma: what constitutes low-risk and how low can one go?"

Novel biological insights have established that medulloblastoma is a

heterogenous disease comprising four broad molecular subgroups—WNT, SHH, Group 3, and Group 4 respectively, resulting in the incorporation of molecular/[genetic information](#) in 5th edition of WHO [classification](#) and contemporary risk-stratification. Concerns regarding therapy-related late [toxicity](#) in long-term survivors have led to systematic attempts at treatment de-intensification in good-risk medulloblastoma.

Given the excellent survival (>90%) of WNT-pathway medulloblastoma, prospective clinical trials have focused on optimization of therapy to balance survival versus quality of survival. The currently accepted definition of low-risk WNT-pathway medulloblastoma includes children

Citation: WNT-pathway medulloblastoma: What constitutes low-risk and how low can one go? (2023, February 27) retrieved 9 April 2024 from <https://medicalxpress.com/news/2023-02-wnt-pathway-medulloblastoma-constitutes-low-risk.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--